CardioSource WorldNews Interventions September 2014 | Page 2

IN THE TREATMENT OF ACUTE CORONARY SYNDROME

DECISIONS TODAY CAN

IMPACT A LIFE
BRILINTA CAN HELP
BEYOND 30 DAYS, BEYOND THE HOSPITAL,
BETTER EFFICACY THAN CLOPIDOGREL
AT 30 DAYS, BRILINTA plus aspirin reduced the primary
composite end point of cardiovascular (CV) death,
myocardial infarction (MI),* or stroke by 12% RRR†
(ARR‡ 0.6%) vs clopidogrel plus aspirin.§1,2

AT 12 MONTHS, BRILINTA plus aspirin significantly
reduced the primary composite end point by 16% RRR
(ARR 1.9%) vs clopidogrel plus aspirin. The difference
between treatments was driven by CV death and MI
with no difference in stroke.§1

IMPORTANT SAFETY INFORMATION ABOUT BRILINTA
WARNING: (A) BLEEDING RISK, (B) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS
A. BLEEDING RISK
B. ASPIRIN DOSE AND BRILINTA EFFECTIVENESS
• BRILINTA, like other antiplatelet agents, can cause
• Maintenance doses of aspirin above 100 mg
significant, sometimes fatal, bleeding
reduce the effectiveness of BRILINTA and should
be avoided. After any initial dose, use with aspirin
• Do not use BRILINTA in patients with active
75 mg - 100 mg per day
pathological bleeding or a history of intracranial
hemorrhage
CONTRAINDICATIONS
• Do not start BRILINTA in patients planned to undergo
• BRILINTA is contraindicated in patients with a
urgent coronary artery bypass graft surgery (CABG).
history of intracranial hemorrhage and active
When possible, discontinue BRILINTA at least 5 days
pathological bleeding such as peptic ulcer or
prior to any surgery
intracranial hemorrhage. BRILINTA is
contraindicated in patients with severe hepatic
• Suspect bleeding in any patient who is hypotensive
impairment because of a probable increase in
and has recently undergone coronary angiography,
exposure; it has not been studied in these patients.
percutaneous coronary intervention (PCI), CABG, or
Severe hepatic impairment increases the risk
other surgical procedures in the setting of BRILINTA
of bleeding because of reduced synthesis
• If possible, manage bleeding without discontinuing
of coagulation proteins. BRILINTA is also
BRILINTA. Stopping BRILINTA increases the risk of
contraindicated in patients with hypersensitivity
subsequent cardiovascular events
(eg, angioedema) to ticagrelor or any component
of the product